FreeStyle Libre version-1 was approved by the FDA in Oct 2017 (#msg-134957213). In 1Q20, the Freestyle Libre franchise had annualized sales of $2.4B, a level rarely attained by a medical device. With the approval of version-2 in the US market, annualized sales should continue their upward trajectory to what some analysts expect will be $5B+.